OTCM
KLDO
Market cap4kUSD
Oct 08, Last price
0.00USD
1D
0.00%
1Q
0.00%
IPO
-100.00%
Name
Kaleido Biosciences Inc
Chart & performance
P/E
—
P/S
0.00
EPS
—
Div yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
0.00%
Revenues
1m
+13.23%
Net income
-90m
L+10.62%
CFO
-77m
L+25.32%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Kaleido Biosciences, Inc. is a clinical-stage healthcare firm dedicated to pioneering microbiome metabolic therapies. Its pipeline includes specific drug candidates such as KB195 for urea cycle disorders, KB295 targeting ulcerative colitis, KB174 aimed at hepatic encephalopathy, and KB109 for COVID-19. The company is also advancing programs in other significant therapeutic areas, including multi-drug resistant infections, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and various inflammatory bowel conditions. Kaleido maintains strategic collaborations with Institute Gustave Roussy, Washington University, and Janssen. Established in 2015, its headquarters are situated in Lexington, Massachusetts.
Key people
Mike Bonney
Chairman of the Board, Chief Executive Officer
Jeffery Moore
Senior Vice President - Finance & Administration
Jeremy Buzzard
Senior Vice President - Corporate Development
Johannes Van Hylckama Vlieg
Chief Scientific Officer · since 2019
Ruth Thieroff-Ekerdt
Chief Medical Officer
Clare Fisher
Chief Business Officer · since 2019
Jerald Korn
General Counsel, Corporate Secretary · since 2019
Bonnie Bassler
Director · since 2018
Grady Burnett
Director · since 2018
Anthony G. Quinn
Director
Theo Melas-Kyriazi
Independent Director · since 2019
Jean K. Mixer
Independent Director · since 2019
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | ||||||
Unusual Expense (Income) | ||||||
NOPBT | ||||||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | ||||||
Net income | ||||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | ||||||
| Cash flow | ||||||
Cash from operating activities | ||||||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | ||||||
FCF | ||||||
| Balance | ||||||
Cash | ||||||
Long term investments | ||||||
Excess cash | ||||||
Stockholders' equity | ||||||
Invested Capital | ||||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | ||||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | ||||||
EV/EBITDA | ||||||
Interest | ||||||
Interest/NOPBT | ||||||